226 related articles for article (PubMed ID: 20089965)
21. The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells.
Dal Bo M; D'Agaro T; Gobessi S; Zucchetto A; Dereani S; Rossi D; Zaja F; Pozzato G; Di Raimondo F; Gaidano G; Laurenti L; Del Poeta G; Efremov DG; Gattei V; Bomben R
Oncotarget; 2015 Aug; 6(22):19102-17. PubMed ID: 26036258
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic implications of activation of the host gene (Dleu2) promoter for miR-15a/16-1 in chronic lymphocytic leukemia.
Kasar S; Underbayev C; Yuan Y; Hanlon M; Aly S; Khan H; Chang V; Batish M; Gavrilova T; Badiane F; Degheidy H; Marti G; Raveche E
Oncogene; 2014 Jun; 33(25):3307-15. PubMed ID: 23995789
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia.
Saddler C; Ouillette P; Kujawski L; Shangary S; Talpaz M; Kaminski M; Erba H; Shedden K; Wang S; Malek SN
Blood; 2008 Feb; 111(3):1584-93. PubMed ID: 17971485
[TBL] [Abstract][Full Text] [Related]
24. The tumor suppressor axis p53/miR-34a regulates Axl expression in B-cell chronic lymphocytic leukemia: implications for therapy in p53-defective CLL patients.
Boysen J; Sinha S; Price-Troska T; Warner SL; Bearss DJ; Viswanatha D; Shanafelt TD; Kay NE; Ghosh AK
Leukemia; 2014 Feb; 28(2):451-5. PubMed ID: 24217154
[No Abstract] [Full Text] [Related]
25. Epigenetic inactivation of mir-34b/c in addition to mir-34a and DAPK1 in chronic lymphocytic leukemia.
Wang LQ; Kwong YL; Wong KF; Kho CS; Jin DY; Tse E; Rosèn A; Chim CS
J Transl Med; 2014 Feb; 12():52. PubMed ID: 24559316
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA expression profiling identifies activated B cell status in chronic lymphocytic leukemia cells.
Li S; Moffett HF; Lu J; Werner L; Zhang H; Ritz J; Neuberg D; Wucherpfennig KW; Brown JR; Novina CD
PLoS One; 2011 Mar; 6(3):e16956. PubMed ID: 21408091
[TBL] [Abstract][Full Text] [Related]
27. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
[TBL] [Abstract][Full Text] [Related]
28. p53-dependent non-coding RNA networks in chronic lymphocytic leukemia.
Blume CJ; Hotz-Wagenblatt A; Hüllein J; Sellner L; Jethwa A; Stolz T; Slabicki M; Lee K; Sharathchandra A; Benner A; Dietrich S; Oakes CC; Dreger P; te Raa D; Kater AP; Jauch A; Merkel O; Oren M; Hielscher T; Zenz T
Leukemia; 2015 Oct; 29(10):2015-23. PubMed ID: 25971364
[TBL] [Abstract][Full Text] [Related]
29. Karyotype-specific microRNA signature in chronic lymphocytic leukemia.
Visone R; Rassenti LZ; Veronese A; Taccioli C; Costinean S; Aguda BD; Volinia S; Ferracin M; Palatini J; Balatti V; Alder H; Negrini M; Kipps TJ; Croce CM
Blood; 2009 Oct; 114(18):3872-9. PubMed ID: 19717645
[TBL] [Abstract][Full Text] [Related]
30. Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients.
Dufour A; Palermo G; Zellmeier E; Mellert G; Duchateau-Nguyen G; Schneider S; Benthaus T; Kakadia PM; Spiekermann K; Hiddemann W; Braess J; Truong S; Patten N; Wu L; Lohmann S; Dornan D; GuhaThakurta D; Yeh RF; Salogub G; Solal-Celigny P; Dmoszynska A; Robak T; Montillo M; Catalano J; Geisler CH; Weisser M; Bohlander SK
Blood; 2013 May; 121(18):3650-7. PubMed ID: 23525797
[TBL] [Abstract][Full Text] [Related]
31. Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network.
Audrito V; Vaisitti T; Rossi D; Gottardi D; D'Arena G; Laurenti L; Gaidano G; Malavasi F; Deaglio S
Cancer Res; 2011 Jul; 71(13):4473-83. PubMed ID: 21565980
[TBL] [Abstract][Full Text] [Related]
32. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis.
Raver-Shapira N; Marciano E; Meiri E; Spector Y; Rosenfeld N; Moskovits N; Bentwich Z; Oren M
Mol Cell; 2007 Jun; 26(5):731-43. PubMed ID: 17540598
[TBL] [Abstract][Full Text] [Related]
33. Potential molecular mechanisms for improved prognosis and outcome with neoadjuvant chemotherapy prior to laparoscopical radical hysterectomy for patients with cervical cancer.
Sun H; Xin J; Lu Z; Wang N; Liu N; Guo Q
Cell Physiol Biochem; 2013; 32(5):1528-40. PubMed ID: 24335178
[TBL] [Abstract][Full Text] [Related]
34. Role of miR-15/16 in CLL.
Pekarsky Y; Croce CM
Cell Death Differ; 2015 Jan; 22(1):6-11. PubMed ID: 24971479
[TBL] [Abstract][Full Text] [Related]
35. Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer.
Han JY; Lee GK; Jang DH; Lee SY; Lee JS
Cancer; 2008 Aug; 113(4):799-807. PubMed ID: 18618574
[TBL] [Abstract][Full Text] [Related]
36. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181.
Pekarsky Y; Santanam U; Cimmino A; Palamarchuk A; Efanov A; Maximov V; Volinia S; Alder H; Liu CG; Rassenti L; Calin GA; Hagan JP; Kipps T; Croce CM
Cancer Res; 2006 Dec; 66(24):11590-3. PubMed ID: 17178851
[TBL] [Abstract][Full Text] [Related]
37. MDM2 SNP309 genotype influences survival of metastatic but not of localized neuroblastoma.
Perfumo C; Parodi S; Mazzocco K; Defferrari R; Inga A; Scarrà GB; Ghiorzo P; Haupt R; Tonini GP; Fronza G
Pediatr Blood Cancer; 2009 Oct; 53(4):576-83. PubMed ID: 19526525
[TBL] [Abstract][Full Text] [Related]
38. Impact of the Mdm2(SNP309-G) allele on a murine model of colorectal cancer.
Zhang X; Pageon L; Post SM
Oncogene; 2015 Aug; 34(33):4412-20. PubMed ID: 25435368
[TBL] [Abstract][Full Text] [Related]
39. 17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation.
Dijkstra MK; van Lom K; Tielemans D; Elstrodt F; Langerak AW; van 't Veer MB; Jongen-Lavrencic M
Leukemia; 2009 Mar; 23(3):625-7. PubMed ID: 18818704
[No Abstract] [Full Text] [Related]
40. miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the Eµ-TCL1 mouse model.
Bresin A; Callegari E; D'Abundo L; Cattani C; Bassi C; Zagatti B; Narducci MG; Caprini E; Pekarsky Y; Croce CM; Sabbioni S; Russo G; Negrini M
Oncotarget; 2015 Aug; 6(23):19807-18. PubMed ID: 26090867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]